A prediction model for reactivation of Langerhans cell histiocytosis based on machine-learning algorithms.

Journal: European journal of dermatology : EJD
PMID:

Abstract

Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasm characterized by the clonal proliferation of myeloid progenitor cells. The reactivation rate of LCH exceeds 30%. However, an effective prediction model to predict reactivation is lacking. To select potential prognostic factors of LCH and construct an easy-to-use predictive model based on machine-learning algorithms. Clinical records of LCH inpatients in the Second Xiangya Hospital of Central South University, from 2008 to 2022, were retrospectively studied. Seventy-six patients were classified into a reactivated/progressive group or a stable group. Clinical features and laboratory outcomes were compared, and machine-learning algorithms were used for building prognostic prediction models. Clinical classification (single-system LCH, multiple-system LCH, and central nervous system/lung LCH), level of anemia, bone involvement, skin involvement, and elevated monocyte count were the best performing factors and were finally chosen for the construction of the prediction models. Our results show that the above-mentioned five factors can be used together in a prediction model for the prognosis of LCH patients. The major limitations of this study include its retrospective nature and the relatively small sample size.

Authors

  • Siqi Tan
    Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, People's Republic of China.
  • Ziyan Chen
    Department of Urology, ZhongNan Hospital, Wuhan University, No. 169 Donghu Road, Wuhan, 430071, Hubei, China.
  • Xuefei Hua
    Division of Hematology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China.
  • Suhan Zhang
    Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China.
  • Yanshan Zhu
    Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China.
  • Ruifang Wu
    Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, China.
  • Yuwen Su
    Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, China.
  • Peng Zhang
    Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry & Chemical Engineering, Shaanxi Normal University, Xi'an, Shaanxi 710062, China.
  • Yu Liu
    Research Center of Information Technology, Beijing Academy of Agriculture and Forestry Science, Beijing, China.